All In Biotech

Drug Trial Radar · NCT07185815

Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine

A Prospective, Dose Escalating, Open Label, Multi-center, Phase I/IIa Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine.

Last checked: Nov 20, 2026Latest source record: May 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Aug 1, 2025

Primary completion

Dec 31, 2026

Study completion Jun 3, 2027

Sponsor

Lead sponsor
Mapi Pharma Ltd.Industry
Sponsor type
Industry
First posted
Sep 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the PK, Safety, Tolerability (all cohorts) and Efficacy (cohort 3), of once-a-month long-acting SC injection of dose escalating Cariprazine Depot in subjects eligible for treatment with oral Cariprazine.

Conditions

  • Schizophrenia
  • Bipolar I Disorder
  • Major Depressive Disorder

Interventions

  • Cariprazine DepotDrug

    One single dose of 22 mg

  • Cariprazine DepotDrug

    One single dose of 44 mg

  • Cariprazine Depot MTDDrug

    Three monthly doses of MTD (maximum tolerated dose)

  • Oral Cariprazine 3 mg/dayDrug

    Oral Cariprazine 3 mg/day for three months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety, rate of adverse events (AEs)Time frame: Through study completion, up to 22 weeks for each subject in the first 2 cohorts and up to 24 weeks for each subject in the 3rd cohort
  2. Plasma concentration of cariprazine and its active metabolites (DCAR, DDCAR)Time frame: Through study completion, up to 22 weeks for each subject in the first 2 cohorts and up to 24 weeks for each subject in the 3rd cohort

Locations

6 sites in 2 countries. Site status is shown where the registry gives one.

  • Mapi Pharma Investigational Site IN-101

    Ahmedabad, India · Recruiting

  • Mapi Pharma Investigational Site IN-102

    Ahmedabad, India · Recruiting

  • Mapi Pharma Investigational Site IL-004

    Beersheba, Israel · Recruiting

  • Mapi Pharma Investigational Site IL-003

    Ness Ziona, Israel · Recruiting

  • Mapi Pharma Investigational Site IL-005

    Ramat Gan, Israel · Recruiting

  • Mapi Pharma Investigational Site IL-001

    Tel Aviv, Israel · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.